Summary:
In patients with type 2 diabetes from the EXSCEL trial, once-weekly GLP-1 receptor agonist exenatide significantly reduced all-cause mortality (ACM) risk compared to conventional cardiovascular (CV) risk factor changes, though it was associated with modest effects on hospitalization for heart failure (hHF) and myocardial infarction (MI).
| PICO | Description |
|---|---|
| Population | Adult patients with type 2 diabetes from the EXSCEL trial. |
| Intervention | Once-weekly GLP-1 receptor agonist exenatide. |
| Comparison | Conventional CV risk factor changes induced over 1-year. |
| Outcome | Exenatide significantly reduced ACM risk. However, observed changes in CV risk factors explained only a moderate proportion of the observed impact on specific outcomes such as hHF and MI. |
Source: Ruth L. Coleman, et al. “Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes: an EXSCEL post hoc analysis.” Read article here.
